A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapy For Patients With Relapsed Follicular Non-Hodgkins Lymphoma.

Trial Profile

A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapy For Patients With Relapsed Follicular Non-Hodgkins Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ibritumomab tiuxetan; Iodine-131 tositumomab; Rituximab; Tositumomab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 May 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov record (NCT00268983)..
    • 15 May 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov record (NCT00268983)..
    • 04 Oct 2010 Planned end date (Apr 2016) added as reported by ClinicalTrials.gov (NCT00268983).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top